PEPG Stock Recent News
PEPG LATEST HEADLINES
NEW YORK , March 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PepGen Inc ("PepGen" or the "Company") (NASDAQ: PEPG). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, NY / ACCESS Newswire / March 15, 2025 / Pomerantz LLP is investigating claims on behalf of investors of PepGen Inc ("PepGen" or the "Company") (NASDAQ:PEPG). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of PepGen Inc. ("PepGen Inc.") (NASDAQ:PEPG) concerning possible violations of federal securities laws. PepGen issued a press release "announc[ing] its voluntary decision to temporarily pause the Phase 2 CONNECT2-EDO51 study of PGN-EDO51 in patients with Duchenne muscular dystrophy (DMD) until the Company can review results from the 10 mg/kg cohort in the ongoing Phase 2 CONNECT1-EDO51 study.
NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of PepGen Inc ("PepGen" or the "Company") (NASDAQ:PEPG). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the Company will be presenting two oral presentations as well as five posters at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, being held March 16-19, 2025 in Dallas, TX. The oral presentations.
NEW YORK, NY / ACCESS Newswire / March 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of PepGen Inc ("PepGen" or the "Company") (NASDAQ:PEPG). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
On Tuesday, PepGen Inc. PEPG announced its voluntary decision to temporarily pause the Phase 2 CONNECT2-EDO51 study of PGN-EDO51 in patients with Duchenne muscular dystrophy (DMD) until the company can review results from the 10 mg/kg cohort.
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that management will participate in the following upcoming investor conferences: Leerink Partners Global Healthcare Conference 2025 (Miami, FL) Tuesday, March 11, 2025 at 3:00 p.m. ET, Fireside Chat Stifel 2025 Virtual CNS Forum Wednesda.
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for the quarter and year-ended December 31, 2024, and recent corporate highlights. “Today, we reported initial results from FREEDOM-DM1, which showed robust splicing correction in patients with DM1 following a single dos.
NEW YORK, NY / ACCESS Newswire / February 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or the "Company") (NASDAQ:PEPG). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.